South Africa has commenced its first clinical trial for a locally developed and manufactured oral cholera vaccine. The announcement was made by Health Minister Dr Aaron Motsoaledi on Tuesday at Johannesburg’s Chris Hani Baragwanath Academic Hospital — one of Africa’s largest teaching hospitals.
The vaccine, produced entirely within South African research and manufacturing systems, marks a historic moment for national and continental public health infrastructure. It is the first time a vaccine intended for pivotal clinical trials has been conceptualised, formulated, and produced domestically, underscoring South Africa’s emerging role in global vaccine innovation.
Dr Motsoaledi emphasised the broader implications of this development, noting that “this milestone is about reclaiming our country’s capability to innovate, to manufacture vaccines, and to protect the health of our own people, the people of Africa, and global recipients through global procurement processes.”
Although South Africa is not officially classified as a cholera-endemic country, it has periodically recorded outbreaks, often in the aftermath of cross-border health emergencies. Earlier in 2024, the Department of Health reported 46 confirmed cholera cases, many of which were linked to severe outbreaks in neighbouring countries such as Zambia and Zimbabwe. Those outbreaks led to hundreds of deaths, underscoring the regional interconnectedness of public health and the necessity of cross-border preparedness.
Cholera, a waterborne disease typically spread through contaminated food or water, remains a persistent threat in areas lacking consistent access to safe water and sanitation. The World Health Organization (WHO) has identified several countries in sub-Saharan Africa as cholera hotspots, particularly during seasonal floods and humanitarian crises. The recent outbreaks further highlight how epidemics in one country can rapidly escalate into regional health emergencies if structural vulnerabilities persist.
South Africa’s decision to invest in domestic vaccine development arises from hard-earned lessons during the COVID-19 pandemic, when the continent experienced significant delays in vaccine access due to global supply chain inequities and procurement bottlenecks. At the height of the pandemic, many African countries were among the last to receive vaccine shipments despite being among the most in need.
“Building local vaccine manufacturing capability is not a luxury; it is a national necessity,” Dr Motsoaledi stated. “It ensures that our people are not left behind when the next global health crisis strikes.” His remarks reflect a broader pan-African sentiment that prioritises sovereignty, resilience, and regional solidarity over dependency on external actors in health security.
This clinical trial also represents a critical inflection point in the evolving narrative of African scientific capacity. The tendency to portray African countries as passive recipients of medical interventions is increasingly being replaced by a more accurate picture of African nations as active contributors to global scientific knowledge and innovation. This shift challenges enduring stereotypes and redirects attention towards local expertise, homegrown innovation, and intra-African collaboration.
While the vaccine’s development signals a new chapter for South Africa’s biotech and pharmaceutical sectors, its success will depend on the outcome of rigorous clinical trials. These trials are expected to assess the vaccine’s efficacy, safety, and logistical viability in public health campaigns both within South Africa and across the continent. If successful, the vaccine could significantly augment regional and global efforts to mitigate the recurring threat of cholera, especially in areas where climate change, displacement, and infrastructural deficits exacerbate the risk of outbreaks.
Stakeholders across public health, science, and policy have lauded the trial as a critical intervention that demonstrates Africa’s capability to respond proactively to health challenges rather than reactively. With South Africa leading this initiative, there is a renewed sense of possibility around reconfiguring the continent’s role in global health governance.
As the clinical trials progress, the broader health community — both within Africa and internationally — will be watching closely, not only for the scientific outcomes but for what they symbolise: a continent reclaiming the right and capacity to shape its own health futures.
